Drug Pricing: Page 2
-
California files suit against PBMs over insulin prices
The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin.
By Hailey Mensik • Jan. 13, 2023 -
HHS lays out timing for drug price negotiations
The agency will begin discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept. 1, 2023.
By Christopher Newman • Jan. 11, 2023 -
Explore the Trendline➔
RocheTrendlineBiosimilars
The arrival this year of lookalike competition to AbbVie’s Humira in the U.S. presents an opportunity, and a test, for the cost-saving potential of biosimilars.
By BioPharma Dive staff -
Sanders to target healthcare costs as leader of influential Senate committee
The longtime congressman and “Medicare for All” proponent will soon assume leadership of the Senate HELP committee, giving him sway in one of the nation’s most broadly influential health policy forums.
By Sydney Halleman • Jan. 9, 2023 -
New Alzheimer's drugs
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.
By Ned Pagliarulo • Jan. 6, 2023 -
Pharma companies boost drug prices to start year, but hikes lag inflation
Analysts noted hundreds of list price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.
By Jonathan Gardner • Jan. 3, 2023 -
Gene therapy approval won, Bluebird takes on next challenge: selling it
The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.
By Ned Pagliarulo • Dec. 12, 2022 -
Sponsored by First Republic Bank
Life science investment outlook: thinking beyond the pandemic
Learn about the investment landscape for life science companies, heading into 2023.
Dec. 12, 2022 -
Sanders poised to lead Senate health committee
The longtime pharma critic is set to become chair of the HELP Committee, a post that holds significant power in directing congressional efforts on healthcare issues.
By Susan Kelly • Nov. 28, 2022 -
FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar
Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.
By Christopher Newman • Nov. 18, 2022 -
Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says
The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.
By Rebecca Pifer • Nov. 16, 2022 -
EQRx redraws ‘radical’ drug pricing plans for first two drugs
The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.
By Jonathan Gardner • Nov. 10, 2022 -
Pharma earnings outline drug law’s looming impact on sales, development
While companies remain unsure of the Inflation Reduction Act's effects, some began to warn investors about the likelihood of lower sales and reduced profits.
By Christopher Newman • Nov. 9, 2022 -
Khanchit+khirisutchaluai/Shutterstock.com
Sponsored by GoodRxInflation Reduction Act: What are the healthcare implications?
The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.
Oct. 31, 2022 -
Sponsored by GoodRx
Worried about provider consolidation? Learn about GoodRx engagement solutions
GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.
Oct. 10, 2022 -
ALS drug development
Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost
The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog believes to be reasonable, given its purported benefit.
By Jacob Bell • Sept. 30, 2022 -
Novartis warns of sales hit after federal court turns back patent appeal
The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.
By Kristin Jensen • Sept. 21, 2022 -
Deep Dive
Can biosimilars, after years of limited impact, finally make a mark in the US?
Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.
By Jonathan Gardner • Sept. 7, 2022 -
Q&A
Akili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment
With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.
By Elise Reuter • Aug. 29, 2022 -
With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.
By Jacob Bell • Aug. 25, 2022 -
With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
Approved for severe beta thalassemia, Zynteglo will test insurers’ willingness to pay for expensive one-time treatments. Its market launch is likely to be watched carefully by other gene therapy developers.
By Ned Pagliarulo • Aug. 18, 2022 -
Pharma industry braces as drug pricing bill passes Congress
The Inflation Reduction Act, signed into law by President Biden in August, was one of the most significant political defeats for the industry in years, and will reshape companies’ business plans moving forward.
By Christopher Newman • Aug. 15, 2022 -
Senate passage of drug pricing bill brings major defeat closer for pharma industry
The legislation, which would allow Medicare to negotiate prices on up to 60 drugs by 2029, passed on a party-line vote and now goes to the House, where it is expected to pass.
By Christopher Newman • Aug. 8, 2022 -
Pharma CEOs press case against drug price negotiation as bill gains support
On earnings calls with investors, executives reiterated opposition to legislation advanced by Democrats that would curtail their pricing power in the U.S.
By Christopher Newman • Aug. 4, 2022 -
Roche digs deeper into gene therapy for the eye
The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments.
By Jonathan Gardner • July 20, 2022 -
UnitedHealth to offer some drugs, including insulin, at no cost share in 2023
The initiative aims to address inflationary pressures and prevent worse health outcomes down the line, CEO Andrew Witty told investors Friday.
By Rebecca Pifer • July 15, 2022